447 | POLATUZUMAB‐CONTAINING REGIMENS AS BRIDGE TO CAR‐T: INSIGHTS FROM THE ITALIAN CAR T‐SIE STUDYGiulia Gabrielli, P. L. Zinzani, Benedetta Casadei et al.|Hematological Oncology|2025Cited by 0
Treatability with ibrutinib plus venetoclax in patients with CLL in the real-world. the eric international thrive studyAndrea Visentin, Giuseppe Petruzzellis, Thomas Chatzikonstantinou et al.|Blood|2025Cited by 0
Polatuzumab vedotin–containing regimens as bridge to CART: analysis from the CART-SIE studyGiulia Gabrielli, Pier Luigi Zinzani, Alice Di Rocco et al.|Blood Advances|2026Cited by 0